Inhaled Nitric Oxide Market by Application, End-Users

Description

List of Tables

[190 Pages Report] The Inhaled Nitric Oxide Market size was estimated at USD 778.21 million in 2023 and expected to reach USD 821.09 million in 2024, at a CAGR 5.83% to reach USD 1,157.38 million by 2030.

Inhaled nitric oxide (iNO) is a pulmonary vasodilator used in intensive care medicine to manage acute and chronic pulmonary disorders. It is administered through inhalation, directly reaching the lungs and improving oxygenation by dilating pulmonary blood vessels without significantly affecting blood pressure in other body parts. Its primary use is in neonatal and pediatric populations for conditions including persistent pulmonary hypertension of the newborn (PPHN) and acute respiratory distress syndrome (ARDS). The rising incidence of neonatal conditions requiring iNO therapy, such as PPHN, and an increase in cases of ARDS have significantly propelled the need for inhaled nitric oxide. Additionally, technological advancements enabling portable NO delivery systems have expanded the applicability of the treatments in different care settings, including home care. The ongoing research and potential new indications for iNO in adults with pulmonary diseases offer growth avenues for the market. However, the high cost and stringent regulatory requirements for approval associated with inhaled nitric oxide pose significant barriers to the entry of new players and can limit market growth. Moreover, the exploration of new therapeutic indications and innovations in administration technology that are expected to reduce costs and improve accessibility are promising areas for the inhaled nitric oxide market.

KEY MARKET STATISTICS
Base Year [2023]	USD 778.21 million
Estimated Year [2024]	USD 821.09 million
Forecast Year [2030]	USD 1,157.38 million
CAGR (%)	5.83%

Regional Insights

In the Americas, particularly in the United States and Canada, the adoption of inhaled nitric oxide is increasing rapidly owing to the high prevalence of respiratory diseases and the strong presence of healthcare facilities with advanced technological setups. The FDA's proactive role in approving inhaled nitric oxide products for various medical conditions, including pulmonary arterial hypertension and hypoxic respiratory failure, has bolstered the growth of the inhaled nitric oxide market. Moreover, major players in the pharmaceutical and medical device industries in this region are intensively involved in R&D activities, aiming to expand the application range of inhaled nitric oxide therapy. The EMEA region exhibits a dynamic market for inhaled nitric oxide, with Europe majorly contributing to adoption and innovation. The increasing incidence of neonatal conditions and respiratory diseases in this region has heightened the need for effective therapeutic solutions, including inhaled nitric oxide. Regulatory bodies in Europe, such as the European Medicines Agency (EMA), have laid down stringent guidelines and approval processes, ensuring the safety and efficacy of inhaled nitric oxide products. In the Middle East and Africa, the market is gradually expanding, primarily driven by healthcare infrastructure developments and growing awareness about advanced treatment modalities. The APAC region is witnessing the rapid adoption of inhaled nitric oxide therapies owing to rising healthcare expenditure, an increasing population base, and a growing number of preterm birth incidences. Countries such as China, Japan, and India are at the forefront of this adoption, driven by ongoing healthcare reforms, increasing investments in healthcare infrastructure, and rising awareness about innovative therapeutic options, including inhaled nitric oxide. Furthermore, the presence of a significant number of generic pharmaceutical manufacturers in this region offers cost-effective solutions, making inhaled nitric oxide therapy more accessible to a larger patient population.

Market Insights

Market Dynamics

The market dynamics represent an ever-changing landscape of the Inhaled Nitric Oxide Market by providing actionable insights into factors, including supply and demand levels. Accounting for these factors helps design strategies, make investments, and formulate developments to capitalize on future opportunities. In addition, these factors assist in avoiding potential pitfalls related to political, geographical, technical, social, and economic conditions, highlighting consumer behaviors and influencing manufacturing costs and purchasing decisions.

Market Drivers
- Rising incidents of respiratory disorders worldwide
- Increase in neonatal intensive care facilities with growing healthcare expenditure

Market Restraints
- High cost associated with treatments involving inhaled nitric oxide

Market Opportunities
- Improvements in production and storage technologies of inhaled nitric oxide
- Continuous research to boost the application of inhaled nitric oxide

Market Challenges
- Stringent government regulations for inhaled nitric oxide usage

Market Segmentation Analysis
- Application: Increasing incidences of chronic obstructive pulmonary disease
- End-Users: Growing deployment of inhaled nitric oxide devices in hospitals for neonatal and intensive care units

Market Disruption Analysis
Porter's Five Forces Analysis
Value Chain & Critical Path Analysis
Pricing Analysis
Technology Analysis
Patent Analysis
Trade Analysis
Regulatory Framework Analysis

FPNV Positioning Matrix

The FPNV positioning matrix is essential in evaluating the market positioning of the vendors in the Inhaled Nitric Oxide Market. This matrix offers a comprehensive assessment of vendors, examining critical metrics related to business strategy and product satisfaction. This in-depth assessment empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success, namely Forefront (F), Pathfinder (P), Niche (N), or Vital (V).

Market Share Analysis

The market share analysis is a comprehensive tool that provides an insightful and in-depth assessment of the current state of vendors in the Inhaled Nitric Oxide Market. By meticulously comparing and analyzing vendor contributions, companies are offered a greater understanding of their performance and the challenges they face when competing for market share. These contributions include overall revenue, customer base, and other vital metrics. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With these illustrative details, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.

Recent Developments

Vero Biotech Secures USD 65 Million Credit Facility for Nitric Oxide Delivery System

Vero Biotech has secured a USD 65 million credit facility earmarked for the enhancement of its innovative nitric oxide delivery system. This strategic financial infusion is poised to revolutionize the administration of inhaled nitric oxide, a critical treatment for patients grappling with respiratory conditions. By leveraging this considerable investment, Vero Biotech aims to further refine its delivery technology, underscoring its commitment to advancing respiratory care and improving patient outcomes. [Published On: 2024-02-07]

Third Pole Doses First Patient in Trial with Nitric Oxide Delivery System

Third Pole Therapeutics has initiated a pioneering early feasibility trial, marking a significant advancement in the treatment of pulmonary hypertension related to interstitial lung disease (PH-ILD) with the first patient being dosed with its innovative portable inhaled nitric oxide (iNO) delivery system, the eNOfit device. This multi-center trial (NCT05867914) aims to assess the safety and tolerability of the eNOfit device, which heralds new possibilities for ambulatory treatment. [Published On: 2023-12-12]

Mallinckrodt Announces FDA Clearance of the INOmax EVOLVE DS Delivery System and Approval of the INOmax (Nitric Oxide) Mini-Cylinder

Mallinckrodt PLC announces the FDA clearance of its cutting-edge INOmax EVOLVE DS delivery system for administering INOmax (nitric oxide gas) for inhalation, marking a significant breakthrough in treating respiratory failure. This system is specifically designed for ventilated patients and ensures a consistent dose of nitric oxide throughout the breathing process by leveraging a unique injector module for precise synchronization and dosage. [Published On: 2023-12-07]

Strategy Analysis & Recommendation

The strategic analysis is essential for organizations seeking a solid foothold in the global marketplace. Companies are better positioned to make informed decisions that align with their long-term aspirations by thoroughly evaluating their current standing in the Inhaled Nitric Oxide Market. This critical assessment involves a thorough analysis of the organization's resources, capabilities, and overall performance to identify its core strengths and areas for improvement.

Key Company Profiles

The report delves into recent significant developments in the Inhaled Nitric Oxide Market, highlighting leading vendors and their innovative profiles. These include Air Liquide SA, Beyond Air, Inc., GE HealthCare Technologies, Inc., Getinge AB, Linde PLC, Mallinckrodt PLC, Matheson Tri-Gas, Inc. by Mitsubishi Chemical Group Corporation, Merck KGaA, NIOX Group PLC, Perma Pure LLC by Halma PLC, SOL Group, Third Pole, Inc., and VERO Biotech Inc..

Market Segmentation & Coverage

This research report categorizes the Inhaled Nitric Oxide Market to forecast the revenues and analyze trends in each of the following sub-markets:

Application
- Acute Respiratory Distress Syndrome
- Chronic Obstructive Pulmonary Disease
- Malaria Treatment
- Neonatal Respiratory Treatment
- Tuberculosis Treatment

End-Users
- Clinic
- Hospital

Region
- Americas
  - Argentina
  - Brazil
  - Canada
  - Mexico
  - United States
    - California
    - Florida
    - Illinois
    - New York
    - Ohio
    - Pennsylvania
    - Texas
- Asia-Pacific
  - Australia
  - China
  - India
  - Indonesia
  - Japan
  - Malaysia
  - Philippines
  - Singapore
  - South Korea
  - Taiwan
  - Thailand
  - Vietnam

Europe, Middle East & Africa
- Denmark
- Egypt
- Finland
- France
- Germany
- Israel
- Italy
- Netherlands
- Nigeria
- Norway
- Poland
- Qatar
- Russia
- Saudi Arabia
- South Africa
- Spain
- Sweden
- Switzerland
- Turkey
- United Arab Emirates
- United Kingdom

Product Code: MRR-2D668742FD36

1. Preface

1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders

2. Research Methodology

2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

5.1. Market Dynamics
- 5.1.1. Drivers
  - 5.1.1.1. Rising incidents of respiratory disorders worldwide
  - 5.1.1.2. Increase in neonatal intensive care facilities with growing healthcare expenditure
- 5.1.2. Restraints
  - 5.1.2.1. High cost associated with treatments involving inhaled nitric oxide
- 5.1.3. Opportunities
  - 5.1.3.1. Improvements in production and storage technologies of inhaled nitric oxide
  - 5.1.3.2. Continuous research to boost the application of inhaled nitric oxide
- 5.1.4. Challenges
  - 5.1.4.1. Stringent government regulations for inhaled nitric oxide usage
5.2. Market Segmentation Analysis
- 5.2.1. Application: Increasing incidences of chronic obstructive pulmonary disease
- 5.2.2. End-Users: Growing deployment of inhaled nitric oxide devices in hospitals for neonatal and intensive care units
5.3. Market Trend Analysis
- 5.3.1. Ongoing research activities and approval inhaled nitric oxide products in Americas
- 5.3.2. Growing burden of respiratory disorders improving the adoption of inhaled nitric oxide in the Asia-Pacific
- 5.3.3. Presence of key market players and stringent regulatory landscape for inhaled nitric oxide products across EMEA region
5.4. Cumulative Impact of High Inflation
5.5. Porter's Five Forces Analysis
- 5.5.1. Threat of New Entrants
- 5.5.2. Threat of Substitutes
- 5.5.3. Bargaining Power of Customers
- 5.5.4. Bargaining Power of Suppliers
- 5.5.5. Industry Rivalry
5.6. Value Chain & Critical Path Analysis
5.7. Regulatory Framework Analysis

6. Inhaled Nitric Oxide Market, by Application

6.1. Introduction
6.2. Acute Respiratory Distress Syndrome
6.3. Chronic Obstructive Pulmonary Disease
6.4. Malaria Treatment
6.5. Neonatal Respiratory Treatment
6.6. Tuberculosis Treatment

7. Inhaled Nitric Oxide Market, by End-Users

7.1. Introduction
7.2. Clinic
7.3. Hospital

8. Americas Inhaled Nitric Oxide Market

8.1. Introduction
8.2. Argentina
8.3. Brazil
8.4. Canada
8.5. Mexico
8.6. United States

9. Asia-Pacific Inhaled Nitric Oxide Market

9.1. Introduction
9.2. Australia
9.3. China
9.4. India
9.5. Indonesia
9.6. Japan
9.7. Malaysia
9.8. Philippines
9.9. Singapore
9.10. South Korea
9.11. Taiwan
9.12. Thailand
9.13. Vietnam

10. Europe, Middle East & Africa Inhaled Nitric Oxide Market

10.1. Introduction
10.2. Denmark
10.3. Egypt
10.4. Finland
10.5. France
10.6. Germany
10.7. Israel
10.8. Italy
10.9. Netherlands
10.10. Nigeria
10.11. Norway
10.12. Poland
10.13. Qatar
10.14. Russia
10.15. Saudi Arabia
10.16. South Africa
10.17. Spain
10.18. Sweden
10.19. Switzerland
10.20. Turkey
10.21. United Arab Emirates
10.22. United Kingdom

11. Competitive Landscape

11.1. Market Share Analysis, 2023
11.2. FPNV Positioning Matrix, 2023
11.3. Competitive Scenario Analysis
- 11.3.1. Vero Biotech Secures USD 65 Million Credit Facility for Nitric Oxide Delivery System
- 11.3.2. Third Pole Doses First Patient in Trial with Nitric Oxide Delivery System
- 11.3.3. Mallinckrodt Announces FDA Clearance of the INOmax EVOLVE DS Delivery System and Approval of the INOmax (Nitric Oxide) Mini-Cylinder
- 11.3.4. UAB Researchers Receive Grant to Develop Devices That Can Improve Quality of Life for Patients with Pulmonary Hypertension
- 11.3.5. Beyond Air Secures up to USD 40 Million Debt Financing
- 11.3.6. VERO Biotech Raises USD 30 Million to Accelerate Commercialization of Its Innovative Tankless Inhaled Nitric Oxide Delivery System
- 11.3.7. VERO Biotech Receives FDA Approval of its Third Generation Tankless Inhaled Nitric Oxide Delivery System
- 11.3.8. SaNOtize Announces USD 24 Million in Series B Funding to Advance It's Nitric Oxide-Based Therapeutics, Including Nasal Spray for the Treatment and Prevention of COVID-19

12. Competitive Portfolio

12.1. Key Company Profiles
12.2. Key Product Portfolio